Onco Actu du 9 février 2017

	1. Biologie
NIH study reveals how melanoma spreads [NHGRI] In the next phase of her work, Dr. Loftus and her team will analyze the roles that HIF1α and other transcription factors play in turning genes on and off in melanocytes and melanomas. They will also delve into the newly discovered genes regulated by low oxygen levels that are distinct from HIF1α to better understand the role they have in tumor progression.
How Chemical Probes Can Boost Cancer Research [Cancer Research Catalyst] Chemical probes are small, drug-like molecules that are useful in interrogating biology in disease models. In order for a probe to truly be useful it must have some critical characteristics.
	2. Etiologie
Nanoparticles: The new One True Cause of All Disease? [Respectful Insolence] Give it time, I guess. It wouldn’t surprise me if nanoparticles don’t soon become the new “toxins.” Alternatively, they’ll become the new Morgellon’s disease, with the added benefit that it requires expensive equipment, and not just a regular microscope, to detect nanoparticles. So much more profitable.
Dense breasts may be leading risk factor for breast cancer [Reuters] Researchers examined data on more than 18,000 women with breast malignancies and 184,000 women the same age without breast cancer. They found breast density appeared to be the biggest indicator of cancer risk, even more than other common risk factors like family history or waiting until after age 30 to have babies.
	4.13 Dép., diag. & prono. - Peau
Patient Self Checks Are Critical to Avoid Potentially Deadly Melanoma Recurrence [American College of Surgeons] New study in Journal of the American College of Surgeons finds that recurrent melanomas are more likely to be found by patients as opposed to imaging.
	5. Traitements
The creative science of coining drug names [STAT] Some companies with a new drug to name try to do it in-house with pizza-fueled brainstorming. While that can work, many companies turn to a consultancy like mine that specializes in brand name development.
	5.10 Traitements - Essais
The persistent problem of unregistered clinical trials [BMJ Blogs] Unregistered clinical trials are serious, preventable events that should never happen—and must come first on any list of Research Never Events.
	5.12.5 Immunothérapies - Pharma
Chinese I-O biotech Abbisko raises $28M in first-round funding [FierceBiotech] The investment round—by Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital and TF Capital—will be used to set up R&D teams and discovery centers that will help it advance its core anticancer programs, currently consisting of three preclinical compounds headed by lead candidate ABSK001, which is at the lead optimization stage.
	5.2.2 Pharma - Fusions & Acquisitions
The next PARP buyout? Tesaro shares surge on latest buzz about a buyout [EndPoints] With its PARP drug niraparib under review at the FDA, Tesaro has become one of the most frequently cited takeover targets in biotech, where promising late-stage assets can be hard to find.
	5.4 Traitements - Economie
NICE recommends controlled use of targeted breast cancer radiotherapy treatment alongside further research [NICE] NICE has recommended the Intrabeam Radiotherapy System for people with early breast cancer in limited circumstances with additional data collection.
	6.10.1 Politiques (USA)
Sanders Charges That Big Pharma ‘Owns the United States Congress’ [The Fiscal Times] Pharmaceutical companies have been among the biggest political spenders for years. They've traditionally supported Republican candidates, as they have received 64 percent of industry contributions on average since the 1990 election cycle, according to the Center for Responsive Politics, a watchdog research organization.
	6.11 Patients
The three questions that every patient should ask their doctor [The Guardian] An unimpressed nurse summons the oncology fellow to the chemotherapy chair. “I am not prepared to treat him with chemo. He can barely stay awake.” “But his oncologist wants to push on,” the fellow responds.
	6.6 Publications
ORCID in 2017: Let’s Get this Party Started! [ORCID] Building trust requires the active participation of everyone involved - the individual innovators and the organizations providing innovation infrastructure. That means using your ORCID iD. Integrating ORCID iDs. Ensuring implementation of best practices: authorization, authentication, and automation.
Open Access 2016: A Year of Price Bargaining, Preprints, and a Pirate [Absolutely Maybe] Only 27% of PubMed records added in the last 11 months had full texts.